Compound 21 clinical trials
Also written C21.
How each study uses compound 21 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test compound 21.
- May 2027A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.Phase 2 · Vicore Pharma AB
Studies
Open first, then newest update. How each study uses compound 21 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.Active, not recruitingPhase 2Vicore Pharma ABNCT06588686Written as BuloxibutidHow we know
- Sensitivity of Angiotensin II Type II Receptors in Women Following PreeclampsiaActive, not recruitingEarly Phase 1Anna Stanhewicz, PhDNCT05937841Written as Compound 21How we know
- Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPFCompletedPhase 2Vicore Pharma ABNCT04533022Written as C21How we know
- Effect of C21 on Forearm Blood FlowCompletedPhase 1Vicore Pharma ABNCT05277922Written as C21How we know
- Sex Differences in the Dilatory Response of Compound 21CompletedEarly Phase 1Anna Stanhewicz, PhDNCT05576155Written as Compound 21How we know
- A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 DiabetesCompletedPhase 1Vicore Pharma ABNCT05831644Written as C21How we know
- A Trial to Investigate Recovery From COVID-19 With C21 in Adult SubjectsCompletedPhase 3Vicore Pharma ABNCT04880642Written as C21How we know
- Cold Challenge With C21 in RPCompletedPhase 2Vicore Pharma ABNCT04388176Written as C21How we know
- Safety and Efficacy of C21 in Subjects With COVID-19CompletedPhase 2Vicore Pharma ABNCT04452435Written as C21How we know
Given beside what is tested · 1 — compound 21 is usual care or a partner of the new treatment
Codes
What other systems call compound 21 · ClinicalTrials.gg INT001469
- MeSH (NLM) C000711730compound 21Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) RC2V4W0EYCBULOXIBUTIDConfirmed FDA, NLM, Wikidata
- Wikidata Q27076423compound 21 [PMID: 22802221]Confirmed FDA, NLM, Wikidata
- DrugBank DB18038One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711730 | compound 21 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RC2V4W0EYC | BULOXIBUTID | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27076423 | compound 21 [PMID: 22802221] | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB18038 | — | One source Wikidata |
Also registered as buloxibutid sodium (UNII Y151F1Q61I).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.